Apellis Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2025: USD 1.80 M

Apellis Pharmaceuticals, Inc. Depreciation And Amortization is USD 1.80 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 2.86% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.
  • Apellis Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 1.75 M, a 14.61% change year over year.
  • Apellis Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 1.53 M, a 4.66% change year over year.
  • Apellis Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 1.46 M, a 64.00% change year over year.
  • Apellis Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 889.00 K, a 231.15% change year over year.
Key Data
Date Depreciation And Amortization Dividends Paid Common Stock Issued Common Stock Repurchased